Noah M Ivers1, J-D Schwalm, Cynthia A Jackevicius, Helen Guo, Jack V Tu, Madhu Natarajan. 1. Family Practice Health Centre, Women's College Hospital, Toronto, Ontario, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: noah.ivers@utoronto.ca.
Abstract
BACKGROUND: Patient adherence to cardiac secondary prevention medications declines over time. We examined whether the length of the initial prescription at hospital discharge after coronary angiography would be associated with long-term adherence. METHODS: We conducted a population-level cohort study to examine adherence to cardiac medications for 18 months after coronary angiography in elderly patients with coronary artery disease (CAD). We identified patients with clinical indications for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACE-I/ARB), beta-blockers (BB), and/or statins. In each medication class cohort, we defined high adherence as proportion of days covered (PDC) > 80%. The length of the initial prescription was defined as 0-30 days, 31-60 days, and more than 60 days. We controlled for patient sociodemographic factors, previous adherence, and comorbidities. RESULTS: The ACE-I/ARB cohort included 13,305 patients, the BB cohort included 5,792 patients, and the statin cohort included 16,134 patients. Using < 30 days as the reference, initial prescriptions covering at least 60 days were more likely to result in high long-term adherence for ACE-I/ARB (adjusted odds ratio [aOR], 4.1; 95% confidence interval [CI], 3.6-4.7); BB (aOR, 2.4; 95% CI, 1.9-3.1), and statins (aOR, 3.0; 95% CI, 2.6-3.4). More than 80% of patients had outpatient follow-up with a primary care provider within 30 days, and this did not vary based on length of initial prescription. CONCLUSIONS: Giving patients longer prescriptions for cardiac secondary prevention medications at hospital discharge seems to increase the likelihood of high long-term adherence in elderly patients.
BACKGROUND:Patient adherence to cardiac secondary prevention medications declines over time. We examined whether the length of the initial prescription at hospital discharge after coronary angiography would be associated with long-term adherence. METHODS: We conducted a population-level cohort study to examine adherence to cardiac medications for 18 months after coronary angiography in elderly patients with coronary artery disease (CAD). We identified patients with clinical indications for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACE-I/ARB), beta-blockers (BB), and/or statins. In each medication class cohort, we defined high adherence as proportion of days covered (PDC) > 80%. The length of the initial prescription was defined as 0-30 days, 31-60 days, and more than 60 days. We controlled for patient sociodemographic factors, previous adherence, and comorbidities. RESULTS: The ACE-I/ARB cohort included 13,305 patients, the BB cohort included 5,792 patients, and the statin cohort included 16,134 patients. Using < 30 days as the reference, initial prescriptions covering at least 60 days were more likely to result in high long-term adherence for ACE-I/ARB (adjusted odds ratio [aOR], 4.1; 95% confidence interval [CI], 3.6-4.7); BB (aOR, 2.4; 95% CI, 1.9-3.1), and statins (aOR, 3.0; 95% CI, 2.6-3.4). More than 80% of patients had outpatient follow-up with a primary care provider within 30 days, and this did not vary based on length of initial prescription. CONCLUSIONS: Giving patients longer prescriptions for cardiac secondary prevention medications at hospital discharge seems to increase the likelihood of high long-term adherence in elderly patients.
Authors: Megan E Branda; Marleen Kunneman; Alejandra I Meza-Contreras; Nilay D Shah; Erik P Hess; Annie LeBlanc; Jane A Linderbaum; Danika M Nelson; Margaret R Mc Donah; Carrie Sanvick; Holly K Van Houten; Megan Coylewright; Sara R Dick; Henry H Ting; Victor M Montori Journal: Patient Prefer Adherence Date: 2022-06-01 Impact factor: 2.314
Authors: John A Staples; Guiping Liu; Jeffrey R Brubacher; Ahmer Karimuddin; Jason M Sutherland Journal: J Gen Intern Med Date: 2021-05-04 Impact factor: 5.128
Authors: Holly O Witteman; Justin Presseau; Emily Nicholas Angl; Iffat Jokhio; J D Schwalm; Jeremy M Grimshaw; Beth Bosiak; Madhu K Natarajan; Noah M Ivers Journal: JMIR Hum Factors Date: 2017-03-01
Authors: J D Schwalm; Shuang Di; Tej Sheth; Madhu K Natarajan; Erin O'Brien; Tara McCready; Jeremy Petch Journal: Cardiovasc Digit Health J Date: 2021-12-24
Authors: J D Schwalm; Noah M Ivers; Zachary Bouck; Monica Taljaard; Madhu K Natarajan; Francis Nguyen; Waseem Hijazi; Kednapa Thavorn; Lisa Dolovich; Tara McCready; Erin O'Brien; Jeremy M Grimshaw Journal: BMC Med Date: 2022-06-21 Impact factor: 11.150
Authors: Shane W English; Lauralyn McIntyre; Dean Fergusson; Alexis Turgeon; Marlise P Dos Santos; Cheemun Lum; Michaël Chassé; John Sinclair; Alan Forster; Carl van Walraven Journal: Neurology Date: 2016-09-14 Impact factor: 9.910